Contact
searchSearch
HMP Global
Login

EZH2 Videos

Susan Fineberg, MD, Montefiore Medical Center
Videos
EZH2 Biomarker Predicts Metastatic Disease in Patients With Triple-Negative Breast Cancer Treated With Neoadjuvant Chemotherapy
04/08/2022
Susan Fineberg, MD, overviews EZH2 expression in the neoadjuvant setting to predict metastatic recurrence for patients with TNBC.
Susan Fineberg, MD, overviews EZH2 expression in the neoadjuvant setting to predict metastatic recurrence for patients with TNBC.
Susan Fineberg, MD, overviews...
04/08/2022
Oncology
Dr Leonard
Videos
John Leonard, MD, Discusses the Lymphoma Treatment Landscape
11/04/2021
Dr Leonard discusses the complex landscape and management of patients with lymphoma, including the use of monsunetuzumab therapy.
Dr Leonard discusses the complex landscape and management of patients with lymphoma, including the use of monsunetuzumab therapy.
Dr Leonard discusses the complex...
11/04/2021
Oncology
Dr
Videos
Jeff Kutok, MD, PhD, on Targeting SETD2 in the Treatment of MM
06/28/2021
Dr Kutok discusses preclinical data which were presented at the EHA2021 Virtual Congress that support the targeting of SEDT2 in patients with MM.
Dr Kutok discusses preclinical data which were presented at the EHA2021 Virtual Congress that support the targeting of SEDT2 in patients with MM.
Dr Kutok discusses preclinical...
06/28/2021
Oncology
Dr Evans Discusses Updates in the Treatment of Patients With FL
Videos
Dr Evans Discusses Updates in the Treatment of Patients With FL
01/29/2021
In this video, Andrew Evens, DO, MSc, FACP, discusses a couple of key publications and data sets in the field of EZH2-mutated and EZH2 wild type FL.
In this video, Andrew Evens, DO, MSc, FACP, discusses a couple of key publications and data sets in the field of EZH2-mutated and EZH2 wild type FL.
In this video, Andrew Evens, DO,...
01/29/2021
Oncology
Dr Cook Talks Advancements in the Treatment of FL With EZH2 Inhibitors
Videos
Dr Cook Talks Advancements in the Treatment of FL With EZH2 Inhibitors
11/01/2020
Perry C. Cook, MD, talks about progress made in the use of EZH2 inhibitors for the treatment of patients with FL.
Perry C. Cook, MD, talks about progress made in the use of EZH2 inhibitors for the treatment of patients with FL.
Perry C. Cook, MD, talks about...
11/01/2020
Oncology
Tazemetostat Therapy for Patients With Relapsed/Refractory FL
Videos
Tazemetostat Therapy for Patients With Relapsed/Refractory FL
10/28/2020
Perry C. Cook, MD, discusses the use of tazemetostat for the treatment of patients with relapsed/refractory FL.
Perry C. Cook, MD, discusses the use of tazemetostat for the treatment of patients with relapsed/refractory FL.
Perry C. Cook, MD, discusses the...
10/28/2020
Oncology
Targeting EZH2 in the Context of Follicular Lymphoma
Videos
Targeting EZH2 in the Context of Follicular Lymphoma
09/20/2020
Peter Martin, MD, discusses recent advancements in the treatment of patients with EZH2-positive FL.
Peter Martin, MD, discusses recent advancements in the treatment of patients with EZH2-positive FL.
Peter Martin, MD, discusses...
09/20/2020
Oncology

Recent News

News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use